June 20, 2016
Novartis Pharma said on June 17 that it has filed an application seeking approval for its anti-IgE antibody Xolair (omalizumab) for the treatment of chronic hives. Xolair was approved in Japan in September 2012 for the treatment of bronchial asthma.read more